https://www.statcounter.com/counter/counter.js
Web Analytics
Home » 2019 » May
Greiner Bio-One launches new MiniCollect K2EDTA Capillary Collection Tube

Greiner Bio-One launches new MiniCollect K2EDTA Capillary Collection Tube

Austrian medical technology manufacturer Greiner Bio-One has launched the newly redesigned MiniCollect K2EDTA Capillary Collection Tube, designed for collecting, transporting and evaluating capillary blood samples. The newly redesigned tube has an integrated scoop which allows easy collection of droplets of blood after skin puncture, thus cutting down on the number of accessories needed. When the […]

Cell therapy company Talaris Therapeutics raises $100m in Series A round

Talaris Therapeutics (formerly Regenerex) has raised $100 million in a Series A financing round to advance its allogeneic cell therapy FCR001 into phase 3 development in various immune-related indications. Blackstone Life Sciences led the financing round of the US biotech company with the other participants being Qiming Venture Partners USA and Longitude Capital. Talaris Therapeutics […]

Continue reading …
Teva launches generic version of Delzicol delayed-release capsules in US

Israeli pharma company Teva Pharmaceuticals has launched a generic version of Delzicol (mesalamine) 400mg delayed-release capsules in the US. Mesalamine Delayed-Release capsules are an aminosalicylate, approved for the treatment of mild to moderate ulcerative colitis in patients aged five years and above, and also for maintenance of remission of ulcerative colitis in adult patients. Brendan […]

Continue reading …
Pharma giants bag Lynparza EMA approval for metastatic breast cancer

Lynparza EMA approval : Pharma giants AstraZeneca and MSD have secured an expansion of the European Medical Agency’s (EMA) approval for their poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) to be used for the treatment of a type of advanced breast cancer. The expanded Lynparza EMA approval allows the PARP inhibitor to be used as […]

Continue reading …
Vaxiion begins VAX014 phase 1 trial in non-muscle invasive bladder cancer

Vaxiion Therapeutics, a clinical stage biotech company based in California, has initiated a phase 1 clinical trial of its recombinant bacterial minicell-based oncolytic immunotherapy VAX014 for the treatment of non-muscle invasive bladder cancer (NMIBC). The development comes following the conclusion of a 30-day review of the investigational new drug application (IND) of VAX014 by the […]

Continue reading …
ReGenTree begins ARISE-3 trial of RGN-259 eye drops for dry eye syndrome

ReGenTree has initiated a phase 3 clinical trial, called ARISE-3, to evaluate the safety and efficacy of 0.1% RGN-259 eye drops for the treatment of dry eye syndrome. The company is a US-based joint venture company between GtreeBNT and RegeneRx Biopharmaceuticals. ARISE-3 is a randomized, double-masked, placebo-controlled trial which will evaluate the 0.1% RGN-259 eye […]

Continue reading …
Genentech gets Kadcyla FDA approval for post-surgery treatment of HER2+ EBC

Kadcyla FDA approval : Roche subsidiary Genentech has secured approval from the US Food and Drug Administration (FDA) for its breast cancer drug Kadcyla (ado-trastuzumab emtansine) for post-surgery treatment of HER2-positive early breast cancer (EBC) in patients with residual invasive disease who were subjected to before surgery taxane and Herceptin (trastuzumab)-based treatment. The Kadcyla FDA […]

Continue reading …